The Experts below are selected from a list of 981 Experts worldwide ranked by ideXlab platform
Saomai Dam - One of the best experts on this subject based on the ideXlab platform.
-
potential use of essential oil isolated from cleistocalyx operculatus leaves as a topical Dermatological Agent for treatment of burn wound
Dermatology Research and Practice, 2018Co-Authors: Giabuu Tran, Saomai DamAbstract:Several herbal remedies have been used as topical Agents to cure burn wound, one of the most common injuries in worldwide. In this study, we investigated the potential use of Cleistocalyx operculatus essential oil to treat the burn wound. We identified a total of 13 bioactive compounds of essential oil, several of which exhibited the anti-inflammatory and antimicrobial activities. Furthermore, the essential oil showed the antibacterial effect against S. aureus but not with P. aeruginosa. The supportive effect of essential oil on burn wound healing process also has been proven. Among three groups of mice, wound contraction rate of essential oil treated group (100%) was significantly higher than tamanu oil treated (79%) and control mice (71%) after 20 days ( versus cm2, resp., ). Histological studies revealed that burn wounds treated with essential oil formed a complete epidermal structure, thick and neatly arranged fibers, and scattered immune cells in burn wound. On the contrary, saline treated burn wound formed uneven epidermal layer with necrotic ulcer, infiltration of immune cells, and existence of granulation tissue. This finding demonstrated Cleistocalyx operculatus essential oil as promising topical Dermatological Agent to treat burn wound.
-
Potential Use of Essential Oil Isolated from Cleistocalyx operculatus Leaves as a Topical Dermatological Agent for Treatment of Burn Wound
Hindawi Limited, 2018Co-Authors: Giabuu Tran, Saomai DamAbstract:Several herbal remedies have been used as topical Agents to cure burn wound, one of the most common injuries in worldwide. In this study, we investigated the potential use of Cleistocalyx operculatus essential oil to treat the burn wound. We identified a total of 13 bioactive compounds of essential oil, several of which exhibited the anti-inflammatory and antimicrobial activities. Furthermore, the essential oil showed the antibacterial effect against S. aureus but not with P. aeruginosa. The supportive effect of essential oil on burn wound healing process also has been proven. Among three groups of mice, wound contraction rate of essential oil treated group (100%) was significantly higher than tamanu oil treated (79%) and control mice (71%) after 20 days (0.22±0.03 versus 0.31±0.02 cm2, resp., p
Giabuu Tran - One of the best experts on this subject based on the ideXlab platform.
-
potential use of essential oil isolated from cleistocalyx operculatus leaves as a topical Dermatological Agent for treatment of burn wound
Dermatology Research and Practice, 2018Co-Authors: Giabuu Tran, Saomai DamAbstract:Several herbal remedies have been used as topical Agents to cure burn wound, one of the most common injuries in worldwide. In this study, we investigated the potential use of Cleistocalyx operculatus essential oil to treat the burn wound. We identified a total of 13 bioactive compounds of essential oil, several of which exhibited the anti-inflammatory and antimicrobial activities. Furthermore, the essential oil showed the antibacterial effect against S. aureus but not with P. aeruginosa. The supportive effect of essential oil on burn wound healing process also has been proven. Among three groups of mice, wound contraction rate of essential oil treated group (100%) was significantly higher than tamanu oil treated (79%) and control mice (71%) after 20 days ( versus cm2, resp., ). Histological studies revealed that burn wounds treated with essential oil formed a complete epidermal structure, thick and neatly arranged fibers, and scattered immune cells in burn wound. On the contrary, saline treated burn wound formed uneven epidermal layer with necrotic ulcer, infiltration of immune cells, and existence of granulation tissue. This finding demonstrated Cleistocalyx operculatus essential oil as promising topical Dermatological Agent to treat burn wound.
-
Potential Use of Essential Oil Isolated from Cleistocalyx operculatus Leaves as a Topical Dermatological Agent for Treatment of Burn Wound
Hindawi Limited, 2018Co-Authors: Giabuu Tran, Saomai DamAbstract:Several herbal remedies have been used as topical Agents to cure burn wound, one of the most common injuries in worldwide. In this study, we investigated the potential use of Cleistocalyx operculatus essential oil to treat the burn wound. We identified a total of 13 bioactive compounds of essential oil, several of which exhibited the anti-inflammatory and antimicrobial activities. Furthermore, the essential oil showed the antibacterial effect against S. aureus but not with P. aeruginosa. The supportive effect of essential oil on burn wound healing process also has been proven. Among three groups of mice, wound contraction rate of essential oil treated group (100%) was significantly higher than tamanu oil treated (79%) and control mice (71%) after 20 days (0.22±0.03 versus 0.31±0.02 cm2, resp., p
Yasunori Hase - One of the best experts on this subject based on the ideXlab platform.
-
discovery of a janus kinase inhibitor bearing a highly three dimensional spiro scaffold jte 052 delgocitinib as a new Dermatological Agent to treat inflammatory skin disorders
Journal of Medicinal Chemistry, 2020Co-Authors: Satoru Noji, Yoshinori Hara, Tomoya Miura, Hiroshi Yamanaka, Katsuya Maeda, Akimi Hori, Hiroshi Yamamoto, Shingo Obika, Masafumi Inoue, Yasunori HaseAbstract:Dermatologic disorders such as atopic dermatitis arise from genetic and environmental causes and are complex and multifactorial in nature. Among possible risk factors, aberrant immunological reactions are one of the leading etiologies. Immunosuppressive Agents including topical steroids are common treatments for these disorders. Despite their reliability in clinical settings, topical steroids display side effects, typified by skin thinning. Accordingly, there is a need for alternate effective and well-tolerated therapies. As part of our efforts to investigate new immunomodulators, we have developed a series of JAK inhibitors, which incorporate novel three-dimensional spiro motifs and unexpectedly possess both excellent physicochemical properties and antidermatitis efficacy in the animal models. One of these compounds, JTE-052 (ent-60), also known as delgocitinib, has been shown to be effective and well-tolerated in human clinical trials and has recently been approved in Japan for the treatment of atopic dermatitis as the first drug among Janus kinase inhibitors.
Satoru Noji - One of the best experts on this subject based on the ideXlab platform.
-
discovery of a janus kinase inhibitor bearing a highly three dimensional spiro scaffold jte 052 delgocitinib as a new Dermatological Agent to treat inflammatory skin disorders
Journal of Medicinal Chemistry, 2020Co-Authors: Satoru Noji, Yoshinori Hara, Tomoya Miura, Hiroshi Yamanaka, Katsuya Maeda, Akimi Hori, Hiroshi Yamamoto, Shingo Obika, Masafumi Inoue, Yasunori HaseAbstract:Dermatologic disorders such as atopic dermatitis arise from genetic and environmental causes and are complex and multifactorial in nature. Among possible risk factors, aberrant immunological reactions are one of the leading etiologies. Immunosuppressive Agents including topical steroids are common treatments for these disorders. Despite their reliability in clinical settings, topical steroids display side effects, typified by skin thinning. Accordingly, there is a need for alternate effective and well-tolerated therapies. As part of our efforts to investigate new immunomodulators, we have developed a series of JAK inhibitors, which incorporate novel three-dimensional spiro motifs and unexpectedly possess both excellent physicochemical properties and antidermatitis efficacy in the animal models. One of these compounds, JTE-052 (ent-60), also known as delgocitinib, has been shown to be effective and well-tolerated in human clinical trials and has recently been approved in Japan for the treatment of atopic dermatitis as the first drug among Janus kinase inhibitors.
Yoshinori Hara - One of the best experts on this subject based on the ideXlab platform.
-
discovery of a janus kinase inhibitor bearing a highly three dimensional spiro scaffold jte 052 delgocitinib as a new Dermatological Agent to treat inflammatory skin disorders
Journal of Medicinal Chemistry, 2020Co-Authors: Satoru Noji, Yoshinori Hara, Tomoya Miura, Hiroshi Yamanaka, Katsuya Maeda, Akimi Hori, Hiroshi Yamamoto, Shingo Obika, Masafumi Inoue, Yasunori HaseAbstract:Dermatologic disorders such as atopic dermatitis arise from genetic and environmental causes and are complex and multifactorial in nature. Among possible risk factors, aberrant immunological reactions are one of the leading etiologies. Immunosuppressive Agents including topical steroids are common treatments for these disorders. Despite their reliability in clinical settings, topical steroids display side effects, typified by skin thinning. Accordingly, there is a need for alternate effective and well-tolerated therapies. As part of our efforts to investigate new immunomodulators, we have developed a series of JAK inhibitors, which incorporate novel three-dimensional spiro motifs and unexpectedly possess both excellent physicochemical properties and antidermatitis efficacy in the animal models. One of these compounds, JTE-052 (ent-60), also known as delgocitinib, has been shown to be effective and well-tolerated in human clinical trials and has recently been approved in Japan for the treatment of atopic dermatitis as the first drug among Janus kinase inhibitors.